ardx – Scalper1

Ardelyx Bowel Drug Could Rival Actavis’ Linzess

Newly public biotech Ardelyx (ARDX) reported positive midstage trial data for its bowel-disease drug Wednesday, sending Ardelyx stock up 30.9% to 18.60 in early afternoon trading trading on the stock market today. It made its IPO in June at 14. Ardelyx said that tenapanor, which it’s developing in partnership with AstraZeneca (AZN), met its primary endpoint in a study of 371 sufferers from irritable bowel syndrome with constipation (IBS-C). After

IPO Stock Watch: Biotech Zafgen Up 22% On IPO Debut

Zafgen (ZFGN), a developer of treatments for severe obesity and hunger-related disorders, rose 22% on its IPO debut Thursday. Zafgen raised $96 million by offering 6 million shares at 16, the high end of its range. Another biotech with an initial public offering Thursday was Ardelyx (ARDX), which is developing therapies for late-stage kidney disease. It raised $60 million by offering 4.3 million shares at 14, the midpoint of its range. The stock